

Electronic Acknowledgement Receipt

EFS ID:	8487846
Application Number:	09589288
International Application Number:	
Confirmation Number:	1519
Title of Invention:	METHODS OF INHIBITING B LYMPHOCYTES USING ANTIBODIES TO NEUTROKINE-ALPHA
First Named Inventor/Applicant Name:	Guo-Liang Yu
Customer Number:	73326
Filer:	John Jr. Kilyk/Rebecca Dise
Filer Authorized By:	John Jr. Kilyk
Attorney Docket Number:	PF343P3C5
Receipt Date:	23-SEP-2010
Filing Date:	08-JUN-2000
Time Stamp:	18:45:47
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$940
RAM confirmation Number	7903
Deposit Account	121216
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	FinalRejectioninUS12210134_mailed07212010.pdf	1043224 b388ee08361e8f31ce88b145d79899ec4e8	no	21
Warnings:					
Information:					
2	NPL Documents	El-Hallak-JPediatr-2007.pdf	550253 1e72b4a610e43a88b670199d2c561cf9a663d31a	no	7
Warnings:					
Information:					
3	NPL Documents	Tan-ArthritisRheum-1997.pdf	1024939 7aa59c703a6db19671e1dfeeb225b61ec240a72	no	11
Warnings:					
Information:					
4	NPL Documents	Petri-NEngJMed-2005.pdf	897947 72ccc51407e74248a6f6c82a6770b762d9	no	11
Warnings:					
Information:					
5	NPL Documents	Sauge-Merle-EurJBiochem-1999.pdf	1036416 6d58b42b695810c5ee11b5e6cf127873e395fdd	no	8
Warnings:					
Information:					
6	NPL Documents	Esposito-JImmunol-1999.pdf	1304787 51ee53f02331a138f5d8f79be296da1229a7e33ba0	no	6
Warnings:					
Information:					
7	NPL Documents	InternationalSearchReport-PCT_US01-25850-2003.pdf	304461 2018f81cd73ccf93d8d3a08fec1331b8b5a3b446	no	7
Warnings:					
Information:					
8	NPL Documents	InternationalSearchReport-PCT_US01-25891-2003.pdf	284516 e48b77d71022b8eb8fcaaa1c17a615a049950ba	no	7
Warnings:					
Information:					

9	NPL Documents	RRin09932322_mailed06302004.pdf	282174	no	8
Warnings:					
Information:					
10	NPL Documents	NonFinalRejectionin09932322_mailed02092005.pdf	361079	no	10
Warnings:					
Information:					
11	NPL Documents	FinalRejectionin09932322_mailed08242005.pdf	352168	no	8
Warnings:					
Information:					
12	NPL Documents	NOAin09932322_mailed02082006.pdf	587623	no	11
Warnings:					
Information:					
13	NPL Documents	Han-Virology-1998.pdf	1203721	no	11
Warnings:					
Information:					
14	NPL Documents	NonFinalRejectionin12135025_mailed08042010.pdf	13181985	no	151
Warnings:					
Information:					
15	NPL Documents	NOAinUS11054515_mailed09092010.PDF	934803	no	5
Warnings:					
Information:					
16	NPL Documents	NonFinalRejectionin12605202_mailed09202010.PDF	2057360	no	64
Warnings:					
Information:					
17	NPL Documents	Berenbaum-ClinExpImmunol-1977.pdf	2097647	no	18
Warnings:					
Information:					

18	NPL Documents	Dooley-JAMsocNephrol-1999.pdf	548447 40f8c1b5ea0b6c94b148f1b54441b014ae5328	no	7
Warnings:					
Information:					
19	NPL Documents	Jonsson-IntlImmunopharmacol-2003.pdf	498768 007619468f202905a622e19177f8e44c324841	no	7
Warnings:					
Information:					
20	NPL Documents	Koyama-AnnRheumDis-2005.pdf	396787 3675dcb8bfddbf0ef3265c197270dae379aeed9	no	3
Warnings:					
Information:					
21	NPL Documents	Ramanujam-Jimmunol-2004.pdf	1400623 c21105a8b6b331065d4e1ae098215ab342ea830	no	11
Warnings:					
Information:					
22	NPL Documents	Stohl-ClinImmunol-2002.pdf	747456 56cca5a81e16ae5c7d6fb0425f0ef5bae934ae1	no	8
Warnings:					
Information:					
23	NPL Documents	RRinUS12210134_mailed11302009.pdf	4728183 c865d1dee324ea191288e24ae634804615794411	no	74
Warnings:					
Information:					
24	NPL Documents	1982RevisedCriteriaforClassificationofSLE.pdf	69670 d4fd4ae107d701cc0d0fd41c2008bf85aef396c2	no	2
Warnings:					
Information:					
25	NPL Documents	ResponsetoAppealLetterLilly-EP_0939804-2009.pdf	118815 94bd642e0f8a961b2db16937be1421a4b56105	no	2
Warnings:					
Information:					
26	NPL Documents	ResponsetoAppealLilly-EP_0939804-2009.pdf	3290843 1a5aee708d112d18d61e48b17a8be0f4e23cc	no	50
Warnings:					
Information:					

27	Petition to Withdraw from Issue	PetitionWithdrawFromIssue.pdf	40242 b0f71e5edf989012b9921ed813b713b100e468	no	2
Warnings:					
Information:					
28	Request for Continued Examination (RCE)	RCETransmittal.pdf	80818 e4864bc8377d11418d4f6a640a736d3c94d8a24	no	2
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
29	Amendment Submitted/Entered with Filing of CPA/RCE	Amendment.pdf	510115 834849ba31b597a2f98b18291c7e386ae399dd	no	16
Warnings:					
Information:					
30	Transmittal Letter	IDS-13th.pdf	239608 51c1ca2df9e37f5aac371103f5b858f30a1e5c36	no	5
Warnings:					
Information:					
31	Information Disclosure Statement (IDS) Filed (SB/08)	1449-13th.pdf	737420 f2995c130d896b105f5b5ccdf77220fa066ac30	no	8
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
32	Fee Worksheet (PTO-875)	fee-info.pdf	32662 9b4473de25f3a08f98b2a6ca97e178ac6684f3a0	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			40945560		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.